Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Steger

Showing results (281-290 of 320) with videos related to

Pageof 32
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2019
Continued Endocrine Therapy Is Associated with Improved Survival in Patients with Breast Cancer Brain MetastasesElisabeth S Bergen, Anna S Berghoff, Mela Medjedovic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2011
Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trialGeorg Pfeiler, Robert Königsberg, Christian Fesl, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|June 14, 2021
Androgen Receptor is Expressed in Breast Cancer Brain MetastasesElisabeth S Bergen, Anna S Berghoff, Ariane Steindl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2010
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind studyAlison T Stopeck, Allan Lipton, Jean-Jacques Body, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2010
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancerDavid W Miles, Arlene Chan, Luc Y Dirix, et al.
Breast (Edinburgh, Scotland)|February 17, 2020
Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUTGuenther G Steger, Daniel Egle, Rupert Bartsch, et al.
Breast Care (Basel, Switzerland)|March 12, 2015
Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast CancerElisabeth Bergen, Anna S Berghoff, Margaretha Rudas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2008
Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancerJosé Baselga, Milvia Zambetti, Antoni Llombart-Cussac, et al.
British Journal of Cancer|January 12, 2012
Brain metastases free survival differs between breast cancer subtypesA Berghoff, Z Bago-Horvath, C De Vries, et al.
The Lancet. Oncology|August 10, 2016
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trialChristoph Zielinski, István Láng, Moshe Inbar, et al.
Pageof 32

Showing results (281-290 of 320) with videos related to

Sort By:
Pageof 32
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2019
Continued Endocrine Therapy Is Associated with Improved Survival in Patients with Breast Cancer Brain MetastasesElisabeth S Bergen, Anna S Berghoff, Mela Medjedovic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2011
Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trialGeorg Pfeiler, Robert Königsberg, Christian Fesl, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|June 14, 2021
Androgen Receptor is Expressed in Breast Cancer Brain MetastasesElisabeth S Bergen, Anna S Berghoff, Ariane Steindl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2010
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind studyAlison T Stopeck, Allan Lipton, Jean-Jacques Body, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2010
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancerDavid W Miles, Arlene Chan, Luc Y Dirix, et al.
Breast (Edinburgh, Scotland)|February 17, 2020
Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUTGuenther G Steger, Daniel Egle, Rupert Bartsch, et al.
Breast Care (Basel, Switzerland)|March 12, 2015
Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast CancerElisabeth Bergen, Anna S Berghoff, Margaretha Rudas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2008
Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancerJosé Baselga, Milvia Zambetti, Antoni Llombart-Cussac, et al.
British Journal of Cancer|January 12, 2012
Brain metastases free survival differs between breast cancer subtypesA Berghoff, Z Bago-Horvath, C De Vries, et al.
The Lancet. Oncology|August 10, 2016
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trialChristoph Zielinski, István Láng, Moshe Inbar, et al.
Pageof 32